On Monday, Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was 7.21% up from the session before settling in for the closing price of $7.07. A 52-week range for RXRX has been $5.60 – $15.74.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 132.77% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 2.32%. With a float of $302.41 million, this company’s outstanding shares have now reached $388.78 million.
In terms of profitability, gross margin is 3.01%, operating margin of -620.35%, and the pretax margin is -583.75%.
Recursion Pharmaceuticals Inc (RXRX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Recursion Pharmaceuticals Inc stocks. The insider ownership of Recursion Pharmaceuticals Inc is 22.22%, while institutional ownership is 58.23%. The most recent insider transaction that took place on Nov 21 ’24, was worth 34,702. Before that another transaction happened on Nov 13 ’24, when Company’s Chief Executive Officer sold 20,000 for $7.74, making the entire transaction worth $154,800. This insider now owns 762,656 shares in total.
Recursion Pharmaceuticals Inc (RXRX) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted -0.42 earnings per share (EPS) during the time that was better than consensus figure (set at -0.45) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.48 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.32% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to -43.41% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
You can see what Recursion Pharmaceuticals Inc (RXRX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 50.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.65 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Let’s dig in a bit further. During the last 5-days, its volume was 14.81 million. That was better than the volume of 6.09 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 79.35%. Additionally, its Average True Range was 0.54.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 63.16%, which indicates a significant decrease from 80.98% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 92.74% in the past 14 days, which was higher than the 76.00% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.59, while its 200-day Moving Average is $8.20. However, in the short run, Recursion Pharmaceuticals Inc’s stock first resistance to watch stands at $7.97. Second resistance stands at $8.36. The third major resistance level sits at $8.74. If the price goes on to break the first support level at $7.20, it is likely to go to the next support level at $6.82. Assuming the price breaks the second support level, the third support level stands at $6.43.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
There are 286,641K outstanding shares of the company, which has a market capitalization of 3.27 billion. As of now, sales total 44,580 K while income totals -328,070 K. Its latest quarter income was 26,080 K while its last quarter net income were -95,840 K.